Literature DB >> 25205735

Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.

Liyo Kao1, Vinson Lam1, Meryl Waldman2, Richard J Glassock1, Quansheng Zhu3.   

Abstract

Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. Recent clinical studies established that >70% of patients with idiopathic (also called primary) MN (IMN) possess circulating autoantibodies targeting the M-type phospholipase A2 receptor-1 (PLA2R) on the surface of glomerular visceral epithelial cells (podocytes). In situ, these autoantibodies trigger the formation of immune complexes, which are hypothesized to cause enhanced glomerular permeability to plasma proteins. Indeed, the level of autoantibody in circulation correlates with the severity of proteinuria in patients. The autoantibody only recognizes the nonreduced form of PLA2R, suggesting that disulfide bonds determine the antigenic epitope conformation. Here, we identified the immunodominant epitope region in PLA2R by probing isolated truncated PLA2R extracellular domains with sera from patients with IMN that contain anti-PLA2R autoantibodies. Patient sera specifically recognized a protein complex consisting of the cysteine-rich (CysR), fibronectin-like type II (FnII), and C-type lectin-like domain 1 (CTLD1) domains of PLA2R only under nonreducing conditions. Moreover, absence of either the CysR or CTLD1 domain prevented autoantibody recognition of the remaining domains. Additional analysis suggested that this three-domain complex contains at least one disulfide bond required for conformational configuration and autoantibody binding. Notably, the three-domain complex completely blocked the reactivity of autoantibodies from patient sera with the full-length PLA2R, and the reactivity of patient sera with the three-domain complex on immunoblots equaled the reactivity with full-length PLA2R. These results indicate that the immunodominant epitope in PLA2R is exclusively located in the CysR-FnII-CTLD1 region.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  immunology and pathology; membranous nephropathy; pathophysiology of renal disease and progression

Mesh:

Substances:

Year:  2014        PMID: 25205735      PMCID: PMC4310656          DOI: 10.1681/ASN.2013121315

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  27 in total

Review 1.  Idiopathic membranous nephropathy: an autoimmune disease.

Authors:  Sudesh P Makker; Alfonso Tramontano
Journal:  Semin Nephrol       Date:  2011-07       Impact factor: 5.299

2.  Experimental Models of Membranous Nephropathy.

Authors:  J Ashley Jefferson; Jeffrey W Pippin; Stuart J Shankland
Journal:  Drug Discov Today Dis Models       Date:  2010

3.  Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy.

Authors:  Marieke J H Coenen; Julia M Hofstra; Hanna Debiec; Horia C Stanescu; Alan J Medlar; Bénédicte Stengel; Anne Boland-Augé; Johanne M Groothuismink; Detlef Bockenhauer; Steve H Powis; Peter W Mathieson; Paul E Brenchley; Robert Kleta; Jack F M Wetzels; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

4.  Genetic variants in membranous nephropathy: perhaps a perfect storm rather than a straightforward conformeropathy?

Authors:  David J Salant
Journal:  J Am Soc Nephrol       Date:  2013-03-14       Impact factor: 10.121

Review 5.  The pathogenesis of membranous nephropathy: evolution and revolution.

Authors:  Richard J Glassock
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

Review 6.  Membranous nephropathy: recent travels and new roads ahead.

Authors:  Laurence H Beck; David J Salant
Journal:  Kidney Int       Date:  2010-02-24       Impact factor: 10.612

7.  The mannose receptor family.

Authors:  Lucy East; Clare M Isacke
Journal:  Biochim Biophys Acta       Date:  2002-09-19

8.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Authors:  Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

9.  Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.

Authors:  Durga Kanigicherla; Jennet Gummadova; Edward A McKenzie; Stephen A Roberts; Shelley Harris; Milind Nikam; Kay Poulton; Lorna McWilliam; Colin D Short; Michael Venning; Paul E Brenchley
Journal:  Kidney Int       Date:  2013-01-30       Impact factor: 10.612

10.  Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats.

Authors:  D Kerjaschki; M G Farquhar
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  56 in total

1.  Immune Response against Autoantigen PLA2R Is not Gambling: Implications for Pathophysiology, Prognosis, and Therapy.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2015-12-11       Impact factor: 10.121

2.  Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain.

Authors:  Vincenzo L'Imperio; Federico Pieruzzi; Renato Alberto Sinico; Manuela Nebuloni; Antonio Granata; Andrew Smith; Antonella Radice; Fabio Pagni
Journal:  J Nephrol       Date:  2018-04-06       Impact factor: 3.902

3.  The dominant humoral epitope in phospholipase A2 receptor-1: presentation matters when serving up a slice of π.

Authors:  Laurence H Beck
Journal:  J Am Soc Nephrol       Date:  2014-10-06       Impact factor: 10.121

4.  Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy.

Authors:  Linda Reinhard; Gunther Zahner; Stephan Menzel; Friedrich Koch-Nolte; Rolf A K Stahl; Elion Hoxha
Journal:  J Am Soc Nephrol       Date:  2019-12-16       Impact factor: 10.121

5.  Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy.

Authors:  Peter D Burbelo; Megha Joshi; Adrija Chaturvedi; Dustin J Little; John S Thurlow; Meryl Waldman; Stephen W Olson
Journal:  J Am Soc Nephrol       Date:  2019-12-16       Impact factor: 10.121

6.  MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy.

Authors:  Zhao Cui; Li-Jun Xie; Fang-Jin Chen; Zhi-Yong Pei; Li-Jie Zhang; Zhen Qu; Jing Huang; Qiu-Hua Gu; Yi-Miao Zhang; Xin Wang; Fang Wang; Li-Qiang Meng; Gang Liu; Xu-Jie Zhou; Li Zhu; Ji-Cheng Lv; Fan Liu; Hong Zhang; Yun-Hua Liao; Lu-Hua Lai; Pierre Ronco; Ming-Hui Zhao
Journal:  J Am Soc Nephrol       Date:  2016-11-16       Impact factor: 10.121

7.  Refining Our Understanding of the PLA2R-Antibody Response in Primary Membranous Nephropathy: Looking Forward, Looking Back.

Authors:  Laurence H Beck; David J Salant
Journal:  J Am Soc Nephrol       Date:  2019-12-16       Impact factor: 10.121

Review 8.  Membranous Nephropathy: A Journey From Bench to Bedside.

Authors:  Jean M Francis; Laurence H Beck; David J Salant
Journal:  Am J Kidney Dis       Date:  2016-04-13       Impact factor: 8.860

9.  The Most N-Terminal Region of THSD7A Is the Predominant Target for Autoimmunity in THSD7A-Associated Membranous Nephropathy.

Authors:  Larissa Seifert; Elion Hoxha; Anna M Eichhoff; Gunther Zahner; Silke Dehde; Linda Reinhard; Friedrich Koch-Nolte; Rolf A K Stahl; Nicola M Tomas
Journal:  J Am Soc Nephrol       Date:  2018-03-19       Impact factor: 10.121

Review 10.  Blocking peptides and molecular mimicry as treatment for kidney disease.

Authors:  Andrea Havasi; Weining Lu; Herbert T Cohen; Laurence Beck; Zhiyong Wang; Chinaemare Igwebuike; Steven C Borkan
Journal:  Am J Physiol Renal Physiol       Date:  2016-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.